Cognition Therapeutics, Inc. (CGTX)
USD 0.35
(10.74%)
USD 0.35
(10.74%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Operating Cash Flow | -16.01 Million | -18.53 Million | -3.63 Million | -3.43 Million | -3.09 Million |
| Net Income | -25.78 Million | -21.39 Million | -11.71 Million | -7.83 Million | -4.84 Million |
| Depreciation & Amortization | 252 Thousand | 235 Thousand | 93 Thousand | 98 Thousand | 81 Thousand |
| Deferred income taxes | -2.44 Million | -6.54 Million | -416 Thousand | -70 Thousand | 238 Thousand |
| Stock-based compensation | 4354.00 | 3572.00 | 5183.00 | 475.00 | 361.00 |
| Change in working capital | 4.84 Million | -943 Thousand | 2.84 Million | 3.06 Million | 570 Thousand |
| Other non-cash items | 2.75 Million | 6.54 Million | 383 Thousand | 836 Thousand | 494 Thousand |
| Investing Cash Flow | -147 Thousand | -171 Thousand | -27 Thousand | -10 Thousand | -144 Thousand |
| Investments in PPE | -147 Thousand | -171 Thousand | -27 Thousand | -10 Thousand | -144 Thousand |
| Acquisitions | - | - | - | - | - |
| Investment purchases | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - |
| Other Investing Activities | -147 Thousand | -171 Thousand | -27 Thousand | - | - |
| Financing Cash Flow | 4.52 Million | 5.54 Million | 53.2 Million | 5.76 Million | 2.79 Million |
| Debt repayment | -811 Thousand | -1.39 Million | -268 Thousand | -4000.00 | -50 Thousand |
| Dividends payments | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - |
| Common Stock Issuance | 5.33 Million | 5.32 Million | 44.21 Million | 47 Thousand | - |
| Other Financing Activities | 5.01 Million | 1.61 Million | 9.25 Million | 5.72 Million | 2.84 Million |
| Accounts receivables | 2.39 Million | -1.4 Million | -1.11 Million | 3 Million | -1.11 Million |
| Accounts payables | 2.44 Million | -1.09 Million | 2.16 Million | -364 Thousand | 862 Thousand |
| Inventory | -2.44 Million | 1.4 Million | 1.11 Million | -3 Million | 1.11 Million |
| Other working capital | 2.45 Million | 149 Thousand | 677 Thousand | 3.43 Million | -292 Thousand |
| Cash at beginning of period | 41.56 Million | 54.72 Million | 5.18 Million | 2.89 Million | 3.39 Million |
| Cash at end of period | 29.92 Million | 41.56 Million | 54.72 Million | 5.18 Million | 2.89 Million |
| Capital Expenditure | -147 Thousand | -171 Thousand | -27 Thousand | -10 Thousand | -144 Thousand |
| Effect of forex changes on cash | 4000.00 | -1000.00 | -11 Thousand | -23 Thousand | -60 Thousand |
| Net cash flow / Change in cash | -11.64 Million | -13.15 Million | 49.53 Million | 2.29 Million | -508 Thousand |
| Free Cash Flow | -16.16 Million | -18.7 Million | -3.65 Million | -3.44 Million | -3.24 Million |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -7.04 Million | -9.15 Million | -8.14 Million | -25.78 Million | -6.74 Million | -4.72 Million |
| Depreciation & Amortization | 67 Thousand | 58 Thousand | 66 Thousand | 252 Thousand | 65 Thousand | 61 Thousand |
| Deferred income taxes | - | - | -846 Thousand | -2.44 Million | - | -691 Thousand |
| Stock-based compensation | 1.14 Million | 1.17 Million | 1.07 Million | 4354.00 | 1.07 Million | 1.02 Million |
| Change in working capital | -170 Thousand | 483 Thousand | 1.55 Million | 4.84 Million | 1.44 Million | -56 Thousand |
| Other non-cash items | 1.79 Million | 1.43 Million | 841 Thousand | 2.75 Million | 5000.00 | 691 Thousand |
| Investing Cash Flow | -3000.00 | - | -30 Thousand | -147 Thousand | -58 Thousand | -18 Thousand |
| Investments in PPE | -3000.00 | - | -30 Thousand | -147 Thousand | -58 Thousand | -18 Thousand |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | - | -147 Thousand | -147 Thousand | - | - |
| Financing Cash Flow | -138 Thousand | 11.99 Million | 2.43 Million | 4.52 Million | -3000.00 | 2.09 Million |
| Debt repayment | -181 Thousand | -178 Thousand | -179 Thousand | -811 Thousand | -215 Thousand | -210 Thousand |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | -22 Thousand | -106 Thousand | - | - | - | - |
| Common Stock Issuance | 65 Thousand | 12.27 Million | 2.61 Million | 5.33 Million | 212 Thousand | 2.3 Million |
| Other Financing Activities | -22 Thousand | -106 Thousand | 2439.00 | 5.01 Million | -3.00 | 2095.00 |
| Accounts receivables | -2.23 Million | 420 Thousand | 357 Thousand | 2.39 Million | 755 Thousand | -784 Thousand |
| Accounts payables | 1.72 Million | -377 Thousand | 603 Thousand | 2.44 Million | 672 Thousand | 1.24 Million |
| Inventory | - | - | 3.94 Million | -2.44 Million | -1.42 Million | -456 Thousand |
| Other working capital | 343 Thousand | 440 Thousand | 1.19 Million | 2.45 Million | 1.44 Million | -56 Thousand |
| Cash at beginning of period | 34.67 Million | 29.92 Million | 32.96 Million | 41.56 Million | 37.19 Million | 38.81 Million |
| Cash at end of period | 28.53 Million | 34.67 Million | 29.92 Million | 29.92 Million | 32.96 Million | 37.19 Million |
| Capital Expenditure | -3000.00 | - | -30 Thousand | -147 Thousand | -58 Thousand | -18 Thousand |
| Effect of forex changes on cash | - | - | - | 4000.00 | 1000.00 | -1000.00 |
| Net cash flow / Change in cash | -6.13 Million | 4.74 Million | -3.04 Million | -11.64 Million | -4.22 Million | -1.62 Million |
| Free Cash Flow | -6 Million | -7.24 Million | -5.48 Million | -16.16 Million | -4.21 Million | -3.71 Million |
FMK
OMED
CSCCF
CYDVF
SIIS
LUMAXIND